Natalizumab.

Article Details

Citation

Copy to clipboard

Babaesfahani A, Khanna NR, Kuns B

Natalizumab.

.

PubMed ID

30480940 [ View in PubMed

]

Abstract

Natalizumab is an FDA-approved monoclonal antibody approved for the treatment of multiple sclerosis and Crohn's disease. The drug was originally approved to treat multiple sclerosis in 2004, but after reported cases of death due to progressive multifocal leukoencephalopathy during treatment with natalizumab, the FDA removed the drug from the market. However, in 2006, the FDA reintroduced the drug when multiple protests by those with multiple sclerosis advocated for the use of natalizumab in conjunction with the establishment of an advisory committee that would monitor those on natalizumab. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, monitoring, and toxicity of natalizumab so that providers can direct patient therapy to optimal outcomes for MS patients.

DrugBank Data that Cites this Article

Drugs

Natalizumab

Drug Interactions

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drugs	Interaction
Integrate drug-drug interactions in your software
Natalizumab Denosumab	The risk or severity of immunosuppression can be increased when Denosumab is combined with Natalizumab.
Natalizumab Etanercept	The risk or severity of immunosuppression can be increased when Etanercept is combined with Natalizumab.
Natalizumab Peginterferon alfa-2a	The risk or severity of immunosuppression can be increased when Peginterferon alfa-2a is combined with Natalizumab.
Natalizumab Interferon alfa-n1	The risk or severity of immunosuppression can be increased when Interferon alfa-n1 is combined with Natalizumab.
Natalizumab Interferon alfa-n3	The risk or severity of immunosuppression can be increased when Interferon alfa-n3 is combined with Natalizumab.